Product Details
| Product Name:
Nifurtimox |
CAS No.:
23256-30-6 |
| Purity:
99.87% |
Supply Ability:
10g |
| Release date:
2025/06/16 |
Product Introduction
Bioactivity
| Name | Nifurtimox |
| Description | Nifurtimox (BAY-A-2502) is an antiprotozoal agent (IC50s = 9.91, 12.28, and 10.44 μM against Taluahuén, LQ, and Brener strains of T. cruzi- epimastigotes, respectively). |
| Cell Research | To assess the cell viability after incubation with nifurtimox at different concentrations (10 μg/mL up to 50 μg/mL or 34.8 μM to 174 μM, respectively in the supernatant growth medium) or the vehicle control with according concentrations, all neuroblastoma cell lines were subjected to an MTS assay. Stock solutions of MTS were made at 480 μM in sterile filtered deionized water and stored at ?20°C. Cells were grown to approximately 50% confluency, treated with nifurtimox, and incubated for 1 h with fresh media containing 12 μM MTS. The supernatant was subsequently removed and the cells were lysed with DMSO containing 10% (w/v) sodium dodecyl sulfate (SDS) and 1% (v/v) glacial acetic acid (Carl Roth, #3738). Purple formazan contents of each cell lysate were photometrically analyzed in triplicates at 570 nm (630 nm reference wavelength) in 96 microtiter plates [2]. |
| In vitro | Nifurtimox can produce anion radicals and interfere with oxygen metabolism [1]. On the neuroblastoma cell lines LA-N-1, IMR-32, LS and SK-N-SH, the treatment of nifurtimox shows an increased production of oxidative stress, a reduced lactate dehydrogenase enzyme activity and reduced lactate production. Furthermore, nifurtimox leads to reduced mRNA and protein levels of the proto-oncogene protein N-Myc [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : Insoluble
DMSO : 55 mg/mL (191.44 mM), Sonication is recommended.
|
| Keywords | Parasite | Nifurtimox | LDH | Lactate Dehydrogenase | Inhibitor | inhibit | BAY-A2502 | BAY-A 2502 | BAY2502 | BAY 2502 |
| Inhibitors Related | Kaempferol | Kojic acid | Rotenone | Urethane | Hydroxychloroquine | Metronidazole | Methotrexate disodium | Nitazoxanide | Doxycycline | Artemisinin | Isomalt | DL-Methionine |
| Related Compound Libraries | Glycometabolism Compound Library | Anti-Parasitic Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pediatric Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:388082-77-7
$53.00 / 50mg
-
CAS:20348-23-6
$45.00 / 100mg
-
CAS:19542-67-7
$43.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
![3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine](https://img.chemicalbook.com/ProductImageEN1/2025-06/Large/629891cc-5089-4ef3-a3f3-c5c07659b918.png)
United States